Improvement of primary health care for patients with diabetes

Conditions

Diabetes mellitus type 2 Nutritional, Metabolic, Endocrine Non-insulin-dependent diabetes mellitus

Santos S, Pentzek M, Altiner A, Daubmann A, Drewelow E, Helbig C, Löffler C, Löscher S, Wegscheider K, Abholz HH, Wilm S, Wollny A.

2023-05-134 citations

10.1186/s12875-023-02067-9

Shared decision making and patient-centeredness for patients with poorly controlled type 2 diabetes mellitus in primary care-results of the cluster-randomised controlled DEBATE trial.

Wollny A, Löffler C, Drewelow E, Altiner A, Helbig C, Daubmann A, Wegscheider K, Löscher S, Pentzek M, Wilm S, Feldmeier G, Santos S.

2021-05-156 citations

10.1186/s12875-021-01436-6

Patient-centered communication and shared decision making to reduce HbA1c levels of patients with poorly controlled type 2 diabetes mellitus - results of the cluster-randomized controlled DEBATE trial

Anja Wollny, Attila Altiner, Anne Daubmann, Eva Drewelow, Christian Helbig et al. (11 authors)

BMC Family Practice2019-06-2519 citations

10.1186/s12875-019-0977-9

Interventions

1. Cluster-randomised multi-centre controlled trial with an educative intervention (peer-visit and decision-aid arriba-diabetes) 2. Clusters are composed by GPs and patients 3. The GPs in the interven

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Current inclusion criteria as of 30/06/2015: Patients: 1. Diabetes mellitus type 2 2. HbA1c level of 8.0 or above at the time of recruitment 3. Ability to informed consent 4. Fluency in the German language GPs: 1. General practitioner or internist, working as GP or practitioner with KV admission (Association of Statutory Health Insurance Physicians) Previous inclusion criteria from 10/01/2012 to 30/06/2015: Patients: 1. Diabetes mellitus type 2 2. HbA1c level of 8.1 or above at the time of recruitment 3. Ability to informed consent 4. Fluency in the German language GPs: 1. General practitioner or internist, working as GP or practitioner with KV admission (Association of Statutory Health Insurance Physicians) Original inclusion criteria until 10/01/2012: Patients: 1. Diabetes mellitus type 2 2. HbA1c level of 8.5 or above at the time of recruitment 3. Ability to informed consent 4. Fluency in the German language GPs: 1. General practitioner or internist, working as GP or practitioner with KV admission (Association of Statutory Health Insurance Physicians) 2. Participation on the Disease Management Program diabetes mellitus type 2

Exclusion criteria

Exclusion criteria: 1. Severe comorbidity 2. Life expectancy of less than 18 months

Design outcomes

Primary

Measure	Time frame
Current primary outcome as of 10/01/2012 1. Change of HbA1c at 6, 12, 18, 24 months compared to HbA1c at baseline 2. HbA1c will be measured as routine examinaton, as the case may be within the scope of the German Disease Management Program performed at GP's medical practice Previous primary outcome 1. Change of HbA1c at 6, 12, 18, 24 months compared to HbA1c at baseline 2. HbA1c will be measured as routine examination within the scope of the German Disease Management Program performed at GP's medical practice	—

Measure

Time frame

Current primary outcome as of 10/01/2012 1. Change of HbA1c at 6, 12, 18, 24 months compared to HbA1c at baseline 2. HbA1c will be measured as routine examinaton, as the case may be within the scope of the German Disease Management Program performed at GP's medical practice Previous primary outcome 1. Change of HbA1c at 6, 12, 18, 24 months compared to HbA1c at baseline 2. HbA1c will be measured as routine examination within the scope of the German Disease Management Program performed at GP's medical practice

—

Secondary

Measure	Time frame
Current secondary outcome as of 10/01/2012 1. Patient's evaluation of patient-centeredness and life quality (PACIC-D, PEF-FB-9, BÄK-questionnaire, EQ-5D, PAID) 2. Cardiovascular risk prognosis 3. Pharmacotherapy Previous secondary outcome 1. Patient's evaluation of patient-centeredness and life quality (PACIC-D, PEF-FB-9, SF-36) 2. Cardiovascular risk prognosis 3. Pharmacotherapy	—

Countries

Germany

Outcome results

None listed